What a Peer Review Call from a Pharmacist About Seroquel Means
A peer review call from a pharmacist about Seroquel (quetiapine) means your prescription is being questioned for appropriateness, safety, or adherence to evidence-based guidelines—typically because you're prescribing it off-label (most commonly for insomnia or anxiety) or at doses/durations that raise safety concerns.
Why This Happens
Peer review calls are triggered when:
Off-label prescribing is detected: Quetiapine is FDA-approved only for schizophrenia, bipolar disorder (mania and depression), and as adjunctive treatment for major depressive disorder 1. Any other use—particularly low-dose quetiapine for insomnia—is off-label and lacks robust confirmatory evidence 2.
Safety concerns in vulnerable populations: The FDA mandates a black box warning for increased mortality risk in elderly patients with dementia-related psychosis 1. Recent evidence shows that even low-dose quetiapine (typically prescribed for insomnia) significantly increases mortality (HR 3.1), dementia (HR 8.1), and falls (HR 2.8) compared to trazodone in older adults 3.
Insurance/formulary restrictions: Many payers require prior authorization or peer-to-peer review for quetiapine, especially when prescribed outside FDA-approved indications or in high-risk populations.
What the Pharmacist Is Evaluating
The reviewing pharmacist will assess:
Clinical indication: Is this for an FDA-approved use? If off-label, what is the evidence base and have first-line treatments failed?
Dose appropriateness: Low doses (25-100 mg) suggest off-label use for insomnia or anxiety—indications where 79% of exploratory studies showing "promise" were never followed by confirmatory trials 2.
Patient risk factors: Age >65, dementia, cardiovascular disease, diabetes, history of falls, concurrent QT-prolonging medications, or other antipsychotics 1, 3.
Alternative treatments: Have evidence-based first-line options been tried? For insomnia in older adults, trazodone or mirtazapine carry lower mortality and dementia risk 3.
Common Pitfalls Leading to Peer Review
Prescribing low-dose quetiapine for insomnia in elderly patients: This practice is widespread but dangerous. The 2025 study showed significantly higher mortality and dementia rates even at low doses 3.
Ignoring black box warnings: Prescribing to elderly patients with dementia without documenting informed consent and risk-benefit discussion 1.
Polypharmacy concerns: Combining quetiapine with other sedatives, anticholinergics, or QT-prolonging drugs without documented rationale 4.
Lack of documentation: Failing to document why FDA-approved alternatives were inadequate or contraindicated.
How to Respond to the Peer Review
Be prepared to justify:
Specific FDA-approved indication or detailed rationale for off-label use with documentation of failed first-line treatments.
Risk mitigation: For elderly patients, document baseline cognitive assessment, fall risk evaluation, metabolic parameters (weight, glucose, lipids), and ECG if indicated 1, 3.
Informed consent: Especially for off-label use, document discussion of risks including metabolic effects (weight gain, dyslipidemia even at low doses 5), sedation, falls, and mortality risk in elderly 3.
Monitoring plan: Regular assessment of efficacy, metabolic parameters, movement disorders, and consideration of deprescribing if no clear benefit 4.
Key Safety Considerations
Metabolic effects occur even at low doses: Meta-analysis shows low-dose quetiapine (<200 mg) causes significant weight gain (0.58 kg mean difference) and HDL reduction, with patients 2.12 times more likely to gain ≥7% body weight 5.
Abuse potential exists: Case reports document quetiapine abuse, particularly in patients with substance use disorders, sometimes used intranasally or intravenously for sedative effects 6.
Anticholinergic burden: When switching from quetiapine to non-anticholinergic antipsychotics (aripiprazole, risperidone), cross-tapering is advised to avoid cholinergic rebound 4.
Bottom Line
This peer review is a quality control mechanism to ensure you're prescribing quetiapine appropriately and safely. Given the extensive off-label use without confirmatory evidence 2, significant safety risks in elderly patients 3, and availability of safer alternatives for common off-label indications, be prepared to provide robust clinical justification or consider switching to evidence-based alternatives.